SomnoMedSOMNF 49 Days Payable is 89.80 as of Dec. 2025, which is 28% below its 10-year median of 125.55. GuruFocus rates SOMNF with a GF Score™ of 49/100 and a GF Value™ of $0.33 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 795 Medical Devices & Instruments companies, SomnoMed ranks better than 64.28% on this metric.
SomnoMed's average Accounts Payable for the
six
months ended in Dec. 2025 was $7.68 Mil. SomnoMed's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $15.60 Mil.
Hence, SomnoMed's Days Payable for the
six
months ended in Dec. 2025 was 89.80.
The historical rank and industry rank for SomnoMed's Days Payable or its related term are showing as below:
SOMNF'
s Days Payable Range Over the Past 10 Years
Min: 80.5 Med: 125.55 Max: 147.85
Current: 98.57
During the past 13 years, SomnoMed's highest Days Payable was 147.85. The lowest was 80.50. And the median was 125.55.
SOMNF's Days Payable is ranked better than 64.28% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs SOMNF: 98.57
SomnoMed's Days Payable
declined
from Dec. 2024 (128.77) to Dec. 2025 (89.80).
It may suggest that SomnoMedaccelerated paying its suppliers.
SomnoMed Days Payable Related Terms
SomnoMed Days Payable Historical Data
* Premium members only.
The historical data trend for SomnoMed's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, SomnoMed's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SomnoMed Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's Days Payable distribution charts can be found below:
* The bar in red indicates where SomnoMed's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
SomnoMed's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SomnoMed (SOMNF) has a Days Payable of 89.80 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SomnoMed and its competitors. This is 28% below median its historical median of 125.55. Over the past decade, SomnoMed's Days Payable has ranged from 80.50 to 147.85. According to the industry distribution chart, SomnoMed ranks #284 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 35.7%.
Is SomnoMed's Days Payable too high?
SomnoMed's current Days Payable of 89.80 is 28% below median its 10-year median of 125.55. Over the past 10 years, this metric has ranged from a low of 80.50 to a high of 147.85. The Medical Devices & Instruments industry median Days Payable is 68.07. SomnoMed's value of 89.80 is 31.9% above this industry median. Based on the distribution chart, SomnoMed ranks #284 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SomnoMed has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SomnoMed ranks #284 out of 795 companies for Days Payable. This puts SomnoMed in the upper half of its industry. The industry median Days Payable is 68.07. SomnoMed's value of 89.80 is 31.9% above this benchmark. Historically, SomnoMed's own Days Payable has ranged from 80.50 to 147.85 over the past decade. While the company's 10-year median is 125.55 vs. the industry median of 68.07, SomnoMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SomnoMed's current Days Payable of 89.80 is 31.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SomnoMed and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SomnoMed's current Days Payable is 89.80, which is 28% below median its own 10-year median of 125.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (SOMNF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.33, compared to a current price of $0.45 — trading 35.7% above its estimated fair value. The current Days Payable is 89.80, which is 28% below median its 10-year median of 125.55 and 31.9% above the Medical Devices & Instruments industry median of 68.07. SomnoMed's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For SomnoMed (SOMNF), the current Days Payable is 89.80 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SomnoMed (SOMNF) Overvalued in 2026?
Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued.
The current stock price of $0.45 is trading 35.7% above its estimated GF Value™ of $0.33.
GuruFocus considers SomnoMed to be Significantly Overvalued.
Key valuation signals for SOMNF:
Days Payable: 89.80 (28% below median its 10-year median of 125.55)
GF Value™: $0.33 vs. price of $0.45 (35.7% above fair value)
Industry Position: 31.9% above the Medical Devices & Instruments median (#284 of 795)
No single metric tells the full story. See the SOMNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
49GF Score
Get the complete analysis for SOMNF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOMNF has been successfully added to your 
